Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.

Fourteen patients suffering from advanced colorectal (n = 7), pancreatic (n = 4) or gastric (n = 3) carcinomas received treatment with microencapsulated octreotide pamoate 90 mg i.m. every 4 weeks (n = 4), 160 mg i.m. every 4 weeks (n = 4) or 160 mg i.m. every 2 weeks (n = 6). Two patients had stabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Helle, S. I., Geisler, J., Poulsen, J. P., Hestdal, K., Meadows, K., Collins, W., Tveit, K. M., Holly, J. M., Lønning, P. E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062954/
https://www.ncbi.nlm.nih.gov/pubmed/9662244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062954/
https://www.ncbi.nlm.nih.gov/pubmed/9662244

Ejemplares similares